Literature DB >> 23435365

Follow-up practice in endometrial cancer and the association with patient and hospital characteristics: a study from the population-based PROFILES registry.

Kim A H Nicolaije1, Nicole P M Ezendam, M Caroline Vos, Dorry Boll, Johanna M A Pijnenborg, Roy F P M Kruitwagen, Marnix L M Lybeert, Lonneke V van de Poll-Franse.   

Abstract

OBJECTIVE: To examine to what extent endometrial cancer survivors experienced follow-up according to the Dutch national guidelines, and to identify associations between follow-up care consumption and socio-demographic and clinical characteristics, Health-Related Quality of Life (HRQL), and worry (including fear of recurrence). Patients' preferences with the received follow-up care were also evaluated.
METHODS: All patients diagnosed with endometrial cancer FIGO stages I-II between 1999 and 2007, registered in the Eindhoven Cancer Registry (ECR), received a questionnaire including patients' follow-up care consumption, preferences regarding the follow-up schedule, HRQL (SF36 and EORTC-QLQ-EN24), and worry (IOCv2).
RESULTS: 742 (77%) endometrial cancer survivors returned a completed questionnaire. Overall, 19% reported receiving more follow-up visits than recommended by the guidelines. Overconsumption of follow-up care was lowest in follow-up year 1 (13%), and highest in follow-up years 6-10 (27%). In addition, overconsumption was associated with having a comorbid condition, a higher score on the worry subscale, and hospital of treatment. Most patients (83%) felt comfortable with their follow-up schedule. Patients in follow-up years 6-10 felt least comfortable (69%).
CONCLUSION: Follow-up frequency was higher than recommended in a large group of endometrial cancer survivors, mainly in follow-up years 6-10. Moreover, a substantial variation in follow-up practice was observed between the different hospitals. Despite limited evidence to support the use of intensive follow-up schedules, the current study suggests that intensive routine follow-up after endometrial cancer continues to be standard practice. Possibly, patients should be better informed in order to reduce overconsumption and worry.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23435365     DOI: 10.1016/j.ygyno.2013.02.018

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  15 in total

1.  Increased NUCKS expression is a risk factor for poor prognosis and recurrence in endometrial cancer.

Authors:  Tianbo Liu; Shu Tan; Ye Xu; Fanling Meng; Chang Yang; Ge Lou
Journal:  Am J Cancer Res       Date:  2015-11-15       Impact factor: 6.166

2.  Illness perceptions are associated with higher health care use in survivors of endometrial cancer-a study from the population-based PROFILES registry.

Authors:  Melissa S Y Thong; Floortje Mols; Adrian A Kaptein; Dorry Boll; Caroline Vos; Johanna M A Pijnenborg; Lonneke V van de Poll-Franse; Nicole P M Ezendam
Journal:  Support Care Cancer       Date:  2018-09-13       Impact factor: 3.603

3.  Risk factors for paraaortic lymph node metastasis in endometrial cancer.

Authors:  Mustafa Erkan Sari; İbrahim Yalcin; Hanifi Sahin; Mehmet Mutlu Meydanli; Tayfun Gungor
Journal:  Int J Clin Oncol       Date:  2017-05-18       Impact factor: 3.402

4.  Expression analysis of URI/RMP gene in endometrioid adenocarcinoma by tissue microarray immunohistochemistry.

Authors:  Junxia Gu; Yuting Liang; Longwei Qiao; Xiaoyun Li; Xingang Li; Yaojuan Lu; Qiping Zheng
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

5.  Predictive diagnosis of endometrial hyperplasia and personalized therapeutic strategy in women of fertile age.

Authors:  Vadym M Goncharenko; Vasyl A Beniuk; Olga V Kalenska; Olga M Demchenko; Mykola Ya Spivak; Rostyslav V Bubnov
Journal:  EPMA J       Date:  2013-12-06       Impact factor: 6.543

6.  Cost-Consequence Analysis Alongside a Randomised Controlled Trial of Hospital Versus Telephone Follow-Up after Treatment for Endometrial Cancer.

Authors:  Padraig Dixon; Kinta Beaver; Susan Williamson; Chris Sutton; Pierre Martin-Hirsch; William Hollingworth
Journal:  Appl Health Econ Health Policy       Date:  2018-06       Impact factor: 2.561

7.  "Still a Cancer Patient"-Associations of Cancer Identity With Patient-Reported Outcomes and Health Care Use Among Cancer Survivors.

Authors:  Melissa S Y Thong; Eva-Maria Wolschon; Lena Koch-Gallenkamp; Annika Waldmann; Mechthild Waldeyer-Sauerland; Ron Pritzkuleit; Heike Bertram; Hiltraud Kajüter; Andrea Eberle; Bernd Holleczek; Sylke R Zeissig; Hermann Brenner; Volker Arndt
Journal:  JNCI Cancer Spectr       Date:  2018-07-05

8.  Computational analysis for identification of the extracellular matrix molecules involved in endometrial cancer progression.

Authors:  Vijesh Kumar Yadav; Tzong-Yi Lee; Justin Bo-Kai Hsu; Hsien-Da Huang; Wei-Chung Vivian Yang; Tzu-Hao Chang
Journal:  PLoS One       Date:  2020-04-21       Impact factor: 3.240

9.  High nuclear expression of HDGF correlates with disease progression and poor prognosis in human endometrial carcinoma.

Authors:  Lijing Wang; Qingping Jiang; Shengni Hua; Mengyang Zhao; Qiangyun Wu; Qiaofen Fu; Weiyi Fang; Suiqun Guo
Journal:  Dis Markers       Date:  2014-02-17       Impact factor: 3.434

10.  Creation of the Polish version and adaptation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (QLQ-EN24).

Authors:  Maciej Stukan; Kamil Zalewski; Jacek P Grabowski; Marcin Mardas; Steven Jones; Małgorzata Pietrzak-Stukan; Mirosław Dudziak
Journal:  Contemp Oncol (Pozn)       Date:  2014-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.